BioSpace News Archive

Tessera Therapeutics announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company’s Board of Directors.

ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer.

Recursion announced its intention to soon launch its first major multidisciplinary expansion beyond its Utah headquarters, with plans to hire up to 50 people in Toronto by the end of 2021.

Echelon Diagnostics, Inc., a leading provider of genomic healthcare AI imaging and big data solutions, today announced a strategic collaboration with Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum

Biomerica, Inc. (NASDAQ: BMRA) today announced that the Mexican Patent Office has issued a notice of allowance for Biomerica’s patent application pertaining to the Company’s InFoods® technology platform that offers a revolutionary approach in the treatment of patients suffering from Irritable Bowel Syndrome (“IBS”).

Dimensions Health Centres, a psychedelic wellness company offering immersive retreats for reset and renewal, will provide funding to the Faculty of Health Sciences at Queen’s University, to help launch a collaborative space for research and innovation in the field of psychedelics.

Just over half of patients enrolled in TARGET-NASH with non-alcoholic fatty liver disease and with at least one indication for guideline-recommended use of a statin are taking one despite their higher risk of heart disease, according to new research published in Clinical Gastroenterology & Hepatology.

Waters Corporation introduced the Waters™ Arc™ Premier System, the first liquid chromatography system optimized for chromatographic separations on 2.5 – 3.5 micron columns to also feature Waters’ novel MaxPeak™ High Performance Surface technology.

Visus Therapeutics Inc. today announced the appointment of six new senior leaders.

Editorial from highly respected scientific publication outlines potential of coupling a charitable model with quality precision medicine technology to treat underserved ultra-rare disease patient population.